Afatinib is an irreversible inhibitor of epidermal growth factor receptor (EGFR) and ErbB2 (IC50s = 0.5 and 14 nM, respectively). It increases the cytotoxicity of adriamycin in a concentration-dependent manner in multidrug-resistant A549T lung cancer cells overexpressing P-glycoprotein. Afatinib (20 mg/kg) reduces tumor growth in ErbB2-amplified NCI-N87 and NUGC4 gastric cancer mouse xenograft models. Formulations containing afatinib have been used in the treatment of non-small cell lung cancer.

Shipping & Handling

Shipped In

Room Temperature in continental US; may vary elsewhere

Hazardous

Safety & Storage

Storage Temperature

-20°C

Safety Statement

WARNING This product is not for human or veterinary use. Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Regulatory & Compliance

Technical Documents

Datasheet (1)

qxIIZ11492.pdf

MSDS (1)

zCcXf11492m.pdf

Questions & Answers (0)

Citations (0)